Literature DB >> 2461853

Effects of rat gamma- and non-gamma-interferons on the expression of Ia antigen, growth, and differentiated functions of FRTL5 cells.

T Misaki1, D Tramontano, S H Ingbar.   

Abstract

We undertook the present studies with several objectives in mind: 1) to determine whether recombinant rat gamma-interferon (r gamma IFN) would induce expression of the class II major histocompatibility antigen (Ia) in rat thyroid follicular cells (FRTL5) in culture as human gamma IFN does in cultured human thyrocytes; 2) to characterize the properties of this response, if it does indeed occur; 3) to ascertain whether r gamma IFN has any effect on the growth or differentiated function of FRTL5 cells; and 4) to determine how, if at all, effects of r gamma IFN on the growth and function of FRTL5 cells might be related to expression of the Ia antigen. At concentrations between 1 and 30 U/ml, r gamma IFN induced expression of Ia antigen in a concentration-dependent manner. With a supramaximal concentration of r gamma IFN, Ia antigen first appeared between 4 and 16 h and reached a maximum concentration at about 36 h. After removal of r gamma IFN, the Ia antigen concentration remained constant for about 24 h and then declined, becoming undetectable by 72 h. Induction could not be detected in FRTL5 cells cultured with human gamma IFN, rat non-gamma IFN, Concanavalin-A, phytohemagglutinin, or bovine TSH (bTSH). Over the same range of concentrations that induced the Ia antigen, r gamma IFN proved to be a potent inhibitor of the growth of FRTL5 cells induced by a variety of agents. It produced a concentration-dependent inhibition of the stimulation of [3H] thymidine incorporation and cell replication in FRTL5 cells induced by bTSH. This effect was unaccompanied by any inhibition of either the binding of bTSH to FRTL5 cells or the bTSH-induced increase in cellular cAMP concentration induced therein. However, r gamma IFN did inhibit the stimulation of [3H] thymidine incorporation into DNA induced by (Bu)2cAMP. r gamma IFN also inhibited the stimulation of DNA synthesis and cell replication induced by insulin-like growth factor I (IGF-I) without affecting the specific binding of IGF-I, and decreased the extent of stimulation of [3H]thymidine incorporation induced by the phorbol ester tetradecanoyl phorbol acetate (TPA). Thus, r gamma IFN inhibited both the cAMP-dependent pathway of growth activated by TSH, doing so at some post-cAMP locus, and the cAMP-independent pathways of growth regulation that are activated by IGF-I and TPA.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2461853     DOI: 10.1210/endo-123-6-2849

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  5 in total

1.  Effects of recombinant human interferon gamma on human thyroid tissues from patients with Graves' disease and normal subjects transplanted into nude mice.

Authors:  Y Kasuga; S Matsubayashi; Y Sakatsume; N Miller; C Jamieson; R Volpé
Journal:  J Endocrinol Invest       Date:  1990-12       Impact factor: 4.256

2.  Recruitment of T lymphocytes and induction of tumor necrosis factor in thyroid cancer by a local immunotherapy.

Authors:  T Misaki; Y Watanabe; Y Iida; A Hidaka; K Kasagi; H Fukushima; J Konishi
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  The role of interferon-gamma in lymphocytic thyroiditis: its functional and pathological effect on human thyrocytes in culture.

Authors:  A W Kung; L Ma; K S Lau
Journal:  Clin Exp Immunol       Date:  1992-02       Impact factor: 4.330

4.  Induction in vitro of 72-kD heat shock protein in a continuous culture of rat thyroid cells, FRTL5.

Authors:  T Misaki; R Takeuchi; S Miyamoto; A Hirano; K Kasagi; J Konishi
Journal:  Clin Exp Immunol       Date:  1994-11       Impact factor: 4.330

Review 5.  The cytokine storm and thyroid hormone changes in COVID-19.

Authors:  L Croce; D Gangemi; G Ancona; F Liboà; G Bendotti; L Minelli; L Chiovato
Journal:  J Endocrinol Invest       Date:  2021-02-09       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.